UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Health-related quality of life (HRQL) for individuals with self-reported chronic physical and/or mental health conditions: panel survey of an adult sample in the United States

Health and quality of life outcomes, 2012-12, Vol.10 (1), p.154-154, Article 154

2012

Volltextzugriff (PDF)

Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: Impact of modelling assumptions on recent Canadian findings

Applied health economics and health policy, 2011-11, Vol.9 (6), p.351-365

Tunis, Sandra L.

2011

Volltextzugriff (PDF)

A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US

PharmacoEconomics, 2009-01, Vol.27 (9), p.735-744

Tunis, Sandra L.

2009

Volltextzugriff (PDF)

Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada

Clinical therapeutics, 2009-03, Vol.31 (3), p.657-667

2009

Volltextzugriff (PDF)

Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states

The American journal of managed care, 2008-03, Vol.14 (3), p.131-140

2008

Volltextzugriff (PDF)

Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain

Current medical research and opinion, 2010-01, Vol.26 (1), p.163-175

2010

Volltextzugriff (PDF)

Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US

Current medical research and opinion, 2010-01, Vol.26 (1), p.151-162

2010

Volltextzugriff (PDF)

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada

Applied health economics and health policy, 2010, Vol.8 (4), p.267-280

2010

Volltextzugriff (PDF)

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: A resource for economic research

Applied health economics and health policy, 2008, Vol.6 (2-3), p.103-112

2008

Volltextzugriff (PDF)

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis

Current medical research and opinion, 2009-05, Vol.25 (5), p.1273-1284

2009

Volltextzugriff (PDF)

A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US

Current medical research and opinion, 2009-06, Vol.25 (6), p.1343-1353

2009

Volltextzugriff (PDF)

The impact of clinical trial design on cost-effectiveness analyses: illustration from a published study of the one-touch ultrasmart blood glucose meter for insulin-using diabetes patients

Diabetes technology & therapeutics, 2008-06, Vol.10 (3), p.227-231

2008

Volltextzugriff (PDF)

An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia

Current medical research and opinion, 2007-01, Vol.23 (1), p.97-104

2007

Volltextzugriff (PDF)

Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines

Bipolar disorders, 2001-08, Vol.3 (4), p.165-173

2001

Volltextzugriff (PDF)

Assessing the value of antipsychotics for treating schizophrenia: The importance of evaluating and interpreting the clinical significance of individual service costs

PharmacoEconomics, 2004-01, Vol.22 (1), p.1-8

2004

Volltextzugriff (PDF)

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US

Current medical research and opinion, 2008-11, Vol.24 (11), p.3085-3096

2008

Volltextzugriff (PDF)

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Journal of clinical psychopharmacology, 2006-12, Vol.26 (6), p.666-667

2006

Volltextzugriff (PDF)

Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia in Geropsychiatric Inpatients

The American journal of geriatric psychiatry, 2001, Vol.9 (3), p.289-297

2001

Volltextzugriff (PDF)

Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program

The journal of clinical psychiatry, 2002-02, Vol.63 (2), p.108-116

2002

Volltextzugriff (PDF)

Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial

Current medical research and opinion, 2005-04, Vol.21 (4), p.555-564

2005

Volltextzugriff (PDF)

Cost Effectiveness of Self-Monitoring of Blood Glucose (SMBG) for Patients with Type 2 Diabetes and Not on Insulin

Applied health economics and health policy, 2011-11, Vol.9 (6), p.351

Tunis, Sandra L

2011

Volltextzugriff (PDF)

Economic outcomes associated with Switching individuals with schizophrenia between risperidone and olanzapine: Findings from a large US claims database

CNS drugs, 2004-01, Vol.18 (3), p.157-164

2004

Volltextzugriff (PDF)

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Value in health, 2006-03, Vol.9 (2), p.77-89

2006

Volltextzugriff (PDF)

Characterizing Behavioral and Psychological Symptoms of Dementia (BPSD) Among Geropsychiatric Inpatients

Journal of the American Medical Directors Association, 2002-05, Vol.3 (3), p.146-151

2002

Volltextzugriff (PDF)

Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia

Schizophrenia research, 2004-10, Vol.70 (2), p.331-342

2004

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(54)
Dissertationen
(1)

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Thema

Humans
(36)
Science & Technology
(34)
Life Sciences & Biomedicine
(33)
Female
(27)
Male
(25)
Adult
(18)
Middle Aged
(17)
Cost-Benefit Analysis
(15)
Biological And Medical Sciences
(14)
Social Sciences
(13)
Medical Sciences
(12)
Antipsychotic Agents - Therapeutic Use
(11)
Health Care Sciences & Services
(11)
Health Policy & Services
(11)
Treatment Outcome
(11)
Psychology. Psychoanalysis. Psychiatry
(10)
Schizophrenia - Drug Therapy
(10)
Diabetes Mellitus, Type 2 - Drug Therapy
(9)
Diabetes Mellitus, Type 2 - Economics
(8)
General & Internal Medicine
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Health-related quality of life (HRQL) for individuals with self-reported chronic physical and/or mental health conditions: panel survey of an adult sample in the United States

Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: Impact of modelling assumptions on recent Canadian findings

A Cost-Effectiveness Analysis to Illustrate the Impact of Cost Definitions on Results, Interpretations and Comparability of Pharmacoeconomic Studies in the US

Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada

Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states

Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain

Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: A resource for economic research

Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis

A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US

The impact of clinical trial design on cost-effectiveness analyses: illustration from a published study of the one-touch ultrasmart blood glucose meter for insulin-using diabetes patients

An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia

Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines

Assessing the value of antipsychotics for treating schizophrenia: The importance of evaluating and interpreting the clinical significance of individual service costs

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use

Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia in Geropsychiatric Inpatients

Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program

Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial

Cost Effectiveness of Self-Monitoring of Blood Glucose (SMBG) for Patients with Type 2 Diabetes and Not on Insulin

Economic outcomes associated with Switching individuals with schizophrenia between risperidone and olanzapine: Findings from a large US claims database

Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia: Results from a Randomized, Open-Label, 1-Year Trial

Characterizing Behavioral and Psychological Symptoms of Dementia (BPSD) Among Geropsychiatric Inpatients

Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia

Suchergebnisse filtern